Otezla Approval History
- FDA approved: Yes (First approved March 21st, 2014)
- Brand name: Otezla
- Generic name: apremilast
- Dosage form: Tablets
- Company: Celgene Corporation
- Treatment for: Psoriatic Arthritis, Plaque Psoriasis
Otezla (apremilast) is a phosphodiesterase 4 (PDE4) inhibitor indicated for the treatment of psoriatic arthritis and plaque psoriasis.
Development History and FDA Approval Process for Otezla
|Sep 23, 2014||FDA Approves Otezla (apremilast) for Moderate to Severe Plaque Psoriasis|
|Mar 21, 2014||FDA Approves Otezla (apremilast) to Treat Psoriatic Arthritis|
Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.